Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Acetyl coenzyme A: a central metabolite and second messenger
Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F., & Kroemer, G. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.014 · Cited by 1,378
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Functions and mechanisms of non-histone protein acetylation
Narita, T., Weinert, B. T., & Choudhary, C. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0081-3 · Cited by 1,232
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Astrocyte Crosstalk in CNS Inflammation
Linnerbauer, M., Wheeler, M. A., & Quintana, F. J. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.012 · Cited by 989
“HDACs have long been targeted in neurological disorders (Falkenberg and Johnstone, 2014) and multiple reports support a role of HDACs in astrocyte activation and neuroimmune crosstalk (Beurel, 2011; Correa et al.”
BackgroundMetabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“For more information about the usage of HDAC inhibitors, IDH1/2 inhibitors, SAM cycle inhibitors and other inhibitors or activators of epigenetic modulation in cancer, please see the excellent reviews by Falkenberg et al., Eckschlager et al., Wong et al. and Cheng et al. (Falkenberg and Johnstone, 2014; Eckschlager et…”
BackgroundPost-translational modifications in proteins: resources, tools and prediction methods
Ramazi, S., & Zahiri, J. (2021) · Database · doi:10.1093/database/baab012 · Cited by 772
“According to the available evidence, acetylated lysine is vital for cell development, and its dysregulation would lead to serious diseases such as cancer, aging, immune disorders, neurological diseases (Huntington’s disease and Parkinson’s disease) and cardiovascular diseases (56, 59, 60, 61).”
BackgroundSystematic mapping of functional enhancer–promoter connections with CRISPR interference
Fulco, C. P., Munschauer, M., Anyoha, R., Munson, G., Grossman, S. R., Perez, E. M., Kane, M., Cleary, B., Lander, E. S., & Engreitz, J. M. (2016) · Science · doi:10.1126/science.aag2445 · Cited by 643
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
Self-citationPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
“HDAC6 Histone deacetylases (HDACs) are a class of proteases whose main function is to modify the structure of chromosomes and regulate gene expression.(259) HDAC6 belongs to the type II HDAC family, which has unique structural and biological properties.”
BackgroundEpigenetic regulation of ageing: linking environmental inputs to genomic stability
Benayoun, B. A., Pollina, E. A., & Brunet, A. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4048 · Cited by 610
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 576
“Similarly, degradation of HDAC6, a class IIB Zn2+-dependent HDAC, was achieved using a PROTAC incorporating a hydroxamic-acid-based HDAC6 inhibitor and pomalidomide as its E3RE [81].”
BackgroundFunctions of bromodomain-containing proteins and their roles in homeostasis and cancer
Fujisawa, T., & Filippakopoulos, P. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.143 · Cited by 573
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
“Clinically relevant HDACis (ITF-2357, MGCD0103, and MS-275) were selected and paired with Aza based on their known pharmacokinetic parameters (serum maximum concentration [Cmax] and half-life) and enzymatic Ki against key HDAC isoforms (Figure S1A) (Bradner et al., 2010; Falkenberg and Johnstone, 2014; Furlan et al.,…”
The roles of microRNAs in epigenetic regulation
Yao, Q., Chen, Y., & Zhou, X. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.01.024 · Cited by 525
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Søgaard, O. S., Graversen, M. E., Leth, S., Olesen, R., Brinkmann, C. R., Nissen, S. K., Kjaer, A. S., Schleimann, M. H., Denton, P. W., Hey-Cunningham, W. J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005142 · Cited by 516
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition
Hai, Y., & Christianson, D. W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2134 · Cited by 521
Gut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
“Hyperacetylation of the chaperone protein HSP90 can lead to the release and subsequent degradation of various oncogenic client proteins.(9,55) HDAC inhibitors have also been shown to downregulate MYC expression in some solid tumours and leukaemia.”
BackgroundInfluentialMetabolic control of epigenetics in cancer
Kinnaird, A., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.82 · Cited by 420
MicroRNA: A signature for cancer progression
Hussen, B. M., Hidayat, H. J., Salihi, A., Sabir, D. K., Taheri, M., & Ghafouri-Fard, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111528 · Cited by 393
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients
Guo, W., Naujock, M., Fumagalli, L., Vandoorne, T., Baatsen, P., Boon, R., Ordovás, L., Patel, A., Welters, M., Vanwelden, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00911-y · Cited by 373
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Vizioli, M. G., Liu, T., Miller, K. N., Robertson, N. A., Gilroy, K., Lagnado, A. B., Perez-Garcia, A., Kiourtis, C., Dasgupta, N., Lei, X., et al. (2020) · Genes & Development · doi:10.1101/gad.331272.119 · Cited by 359
“Aside from their anticancer activities (Falkenberg and Johnstone 2014), HDACi have been previously reported to suppress inflammation and extend the health span and life span in multiple animal models (Hockly et al. 2003; Tao et al. 2004; Gao et al. 2009; Guan et al. 2009; Krishnan et al. 2011; Hull…”
Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.006 · Cited by 352
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
Yoshida, G. J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01611-0 · Cited by 316
“Given that α-SMApositive activated fibroblasts form a senescenceassociated secretory phenotype loop in response to treatment with HDAC inhibitors [137, 138], re-education of the tumor stroma could be a promising therapeutic strategy.”
BackgroundThe emerging role of epigenetics in human autoimmune disorders
Mazzone, R., Zwergel, C., Artico, M., Taurone, S., Ralli, M., Greco, A., & Mai, A. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0632-2 · Cited by 318
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 309
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Self-citationRational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Miyake, Y., Keusch, J. J., Wang, L., Saito, M., Hess, D., Wang, X., Melancon, B. J., Helquist, P., Gut, H., & Matthias, P. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2140 · Cited by 315
Zerdes, I., Matikas, A., Bergh, J., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 292
“It should be noted that HDAC have pleiotropic effects within both the innate and adaptive immune response, and may thus affect PD-L1 levels via interferons [88].”
BackgroundA novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1
Zhang, E., He, X., Zhang, C., Su, J., Lu, X., Si, X., Chen, J., Yin, D., Han, L., & De, W. (2018) · Genome Biology · doi:10.1186/s13059-018-1523-0 · Cited by 282
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Obata, Y., & Pachnis, V. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.044 · Cited by 277
Patnala, R., Arumugam, T. V., Gupta, N., & Dheen, S. T. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0149-z · Cited by 278
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity
Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N., & Berx, G. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.004 · Cited by 271
“Therefore, possible improvements may come from a next generation of more selective HDAC inhibitors that can minimize the observed side effects and context-dependent variable results [111].”
BackgroundLysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease
Li, P., Ge, J., & Li, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0235-9 · Cited by 269
Bulusu, V., Tumanov, S., Michalopoulou, E., van den Broek, N. J., MacKay, G., Nixon, C., Dhayade, S., Schug, Z. T., Vande Voorde, J., Blyth, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.055 · Cited by 266
SIRT6: Novel Mechanisms and Links to Aging and Disease
Tasselli, L., Zheng, W., & Chua, K. F. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.002 · Cited by 265
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 253
Richards, J. L., Yap, Y. A., McLeod, K. H., Mackay, C. R., & Mariño, E. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.29 · Cited by 250
Hosnedlova, B., Kepinska, M., Skalickova, S., Fernandez, C., Ruttkay-Nedecky, B., Malevu, T. D., Sochor, J., Baron, M., Melcova, M., Zidkova, J., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102209 · Cited by 251
“inhibitors have been developed and are currently tested in clinical trials [190].”
BackgroundHistone modifications and their role in epigenetics of atopy and allergic diseases
Alaskhar Alhamwe, B., Khalaila, R., Wolf, J., von Bülow, V., Harb, H., Alhamdan, F., Hii, C. S., Prescott, S. L., Ferrante, A., Renz, H., et al. (2018) · Allergy, Asthma & Clinical Immunology · doi:10.1186/s13223-018-0259-4 · Cited by 248
“They include proteins containing bromodomains, chromodomains, or Tudor domains [50, 51].”
BackgroundReaders, Writers, and Erasers: Chromatin as the Whiteboard of Heart Disease
Gillette, T. G., & Hill, J. A. (2015) · Circulation Research · doi:10.1161/circresaha.116.303630 · Cited by 241
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gomez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 229
Xin, F., Susiarjo, M., & Bartolomei, M. S. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.05.008 · Cited by 237
Transcriptional Regulation of Antiviral Interferon-Stimulated Genes
Wang, W., Xu, L., Su, J., Peppelenbosch, M. P., & Pan, Q. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.01.001 · Cited by 219
Christmas, B. J., Rafie, C. I., Hopkins, A. C., Scott, B. A., Ma, H. S., Cruz, K. A., Woolman, S., Armstrong, T. D., Connolly, R. M., Azad, N. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0070 · Cited by 219
“ENT þ ICI therapy significantly alters the signaling pathways involved in myeloid function ENT alters the global acetylation state of cells (47), but its effect on subpopulations of myeloid cells has not been thoroughly studied.”
BackgroundEpigenetic treatment of solid tumours: a review of clinical trials
Nervi, C., De Marinis, E., & Codacci-Pisanelli, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0157-2 · Cited by 213
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Hong, X., Kim, E. S., & Guo, H. (2017) · Hepatology · doi:10.1002/hep.29479 · Cited by 205
“In addition, HDACis may also potentially reactivate latent DNA virus infection in patients receiving them as anticancer drugs.((63)) IFN-a is the only approved immunomodulator for CHB treatment.”
InfluentialHistone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Neganova, M. E., Klochkov, S. G., Aleksandrova, Y. R., & Aliev, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.015 · Cited by 197
Epigenetic activities of flavonoids in the prevention and treatment of cancer
Busch, C., Burkard, M., Leischner, C., Lauer, U. M., Frank, J., & Venturelli, S. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0095-z · Cited by 197
Diverse Molecular Targets for Chalcones with Varied Bioactivities
Zhou, B. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000291 · Cited by 195
The Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome
Gujar, H., Weisenberger, D. J., & Liang, G. (2019) · Genes · doi:10.3390/genes10020172 · Cited by 197
“A comprehensive list of histone erasers, writers, and readers and the roles of specific histone tail modifications was previously described [6,22,25,26].”
Backgroundvel Szic, K. S., Declerck, K., Vidaković, M., & Vanden Berghe, W. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0068-2 · Cited by 192
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses
Peng, K., Zheng, Y., Xia, W., & Mao, Z.-W. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00757f · Cited by 188
Recent Progress in Histone Demethylase Inhibitors
McAllister, T. E., England, K. S., Hopkinson, R. J., Brennan, P. E., Kawamura, A., & Schofield, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01758 · Cited by 186
Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Li, X., Li, X., Liu, F., Li, S., & Shi, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00683 · Cited by 168
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Lin, M. Y., de Zoete, M. R., van Putten, J. P. M., & Strijbis, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00554 · Cited by 186
Targeting pan-essential genes in cancer: Challenges and opportunities
Chang, L., Ruiz, P., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 185
“The problem of polypharmacology is not limited to targeting pan-essential genes; however, as pan-essential targets can have highly related family members (e.g., 18 human HDACs, 9 human cyclin-dependent kinases [CDKs]), fewer selective inhibitors may target multiple pan-essential genes.”
InfluentialPaiva, I., Pinho, R., Pavlou, M. A., Hennion, M., Wales, P., Schütz, A.-L., Rajput, A., Szegő, É. M., Kerimoglu, C., Gerhardt, E., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx114 · Cited by 185
“Conversely, in neurons, HDACi confer protection against oxidative stress (20,21) and protect neurons in a mouse model of PD (22).”
BackgroundInfluentialBi, L., Ren, Y., Feng, M., Meng, P., Wang, Q., Chen, W., Jiao, Q., Wang, Y., Du, L., Zhou, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3044 · Cited by 181
“Apart from their success in lymphoma and multiple myeloma (4), the efficacies of inhibitory compounds observed against solid tumors have been disappointing, possibly owing to the lack of specificity (7).”
BackgroundTargeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Wu, H., Yang, K., Zhang, Z., Leisten, E. D., Li, Z., Xie, H., Liu, J., Smith, K. A., Novakova, Z., Barinka, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00516 · Cited by 180
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718823114 · Cited by 190
“This alternative Zn2+-binding mode can be exploited by bulky phenylhydroxamate inhibitors in the active site of HDAC6, even though the binding of these inhibitors would be disfavored in the more sterically constricted active sites of class I HDACs.”
BackgroundInfluentialMikhed, Y., Görlach, A., Knaus, U. G., & Daiber, A. (2015) · Redox Biology · doi:10.1016/j.redox.2015.05.008 · Cited by 180
Jiang, Y.-Y., Jiang, Y., Li, C.-Q., Zhang, Y., Dakle, P., Kaur, H., Deng, J.-W., Lin, R. Y.-T., Han, L., Xie, J.-J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.050 · Cited by 178
Epigenetics in liver disease: from biology to therapeutics
Hardy, T., & Mann, D. A. (2016) · Gut · doi:10.1136/gutjnl-2015-311292 · Cited by 176
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Poirier, J. T., George, J., Owonikoko, T. K., Berns, A., Brambilla, E., Byers, L. A., Carbone, D., Chen, H. J., Christensen, C. L., Dive, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.016 · Cited by 173
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory‐related dysfunction: HDAC2 is a nuclear isoform that reduce tra…”
BackgroundPotent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
He, S., Dong, G., Li, Y., Wu, S., Wang, W., & Sheng, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201915896 · Cited by 167
Epigenetic regulation: A new frontier for biomedical engineers
Chen, Z., Li, S., Subramaniam, S., Shyy, J. Y.-J., & Chien, S. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044720 · Cited by 163
Histone Deacetylases in Bone Development and Skeletal Disorders
Bradley, E. W., Carpio, L. R., van Wijnen, A. J., McGee-Lawrence, M. E., & Westendorf, J. J. (2015) · Physiological Reviews · doi:10.1152/physrev.00004.2015 · Cited by 162
Santamaría Nuñez, G., Robles, C. M. G., Giraudon, C., Martínez-Leal, J. F., Compe, E., Coin, F., Aviles, P., Galmarini, C. M., & Egly, J.-M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0172 · Cited by 161
Zhang, H.-Y., Tian, J.-X., Lian, F.-M., Li, M., Liu, W.-K., Zhen, Z., Liao, J.-Q., & Tong, X.-L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110857 · Cited by 161
Wang, Y.-C., Wang, X., Yu, J., Ma, F., Li, Z., Zhou, Y., Zeng, S., Ma, X., Li, Y.-R., Neal, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23164-2 · Cited by 180
Progress towards a public chemogenomic set for protein kinases and a call for contributions
Drewry, D. H., Wells, C. I., Andrews, D. M., Angell, R. M., Al‐Ali, H., Axtman, A. D., Capuzzi, S. J., Elkins, J. M., Ettmayer, P., Frederiksen, M. U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181585 · Cited by 161
Developments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 162
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
Anguille, S., Smits, E., Bryant, C. E., Acker, H. H. V., Goossens, H., Lion, E., Fromm, P. D., Hart, D. N. J., Tendeloo, V. F. V., & Berneman, Z. N. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009456 · Cited by 152
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 159
Adeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C. G., Dries, R., Li, Y., Liu, S., Wang, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1020 · Cited by 154
Epigenetic effects of selenium and their implications for health
Speckmann, B., & Grune, T. (2015) · Epigenetics · doi:10.1080/15592294.2015.1013792 · Cited by 151
Epigenetics of Stress, Addiction, and Resilience: Therapeutic Implications
Cadet, J. L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9040-y · Cited by 180
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
Szymański, W., Ourailidou, M. E., Velema, W. A., Dekker, F. J., & Feringa, B. L. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201502809 · Cited by 152
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 157
“These inhibitors are divided into five subgroups based on their chemical structure: short-chain fatty acids that include hydroxamic acids, benzamides, cyclic peptides, and sirtuin inhibitors [19,176,191].”
BackgroundClinical landscape of macrophage-reprogramming cancer immunotherapies
Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 182
“Histone deacetylase (HDAC) HDAC family enzymes deacetylate proteins, including histones, and thus epigenetically regulate gene expression [172].”
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.